Search alternatives:
linear decrease » linear increase (Expand Search)
lower decrease » larger decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
linear decrease » linear increase (Expand Search)
lower decrease » larger decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
-
2521
Characteristics of studies (<i>n</i> = 22).
Published 2024“…Consistently, participants receiving ketamine/esketamine had lower depression-related scores at 1- (standardized mean difference [SMD], −0.94; 95%CI, −1.26 to −0.62) and 4–6-week (SMD, −0.89; 95%CI, −1.25 to −0.53) follow-ups. …”
-
2522
-
2523
-
2524
-
2525
Patients’ responses to EQ5-D items.
Published 2024“…Moreover, patients with only an elementary education had significantly lower EQ5-D scores compared to those with a postgraduate education (-0.106, 95%CI (-0.190, -0.023), p = 0.013).…”
-
2526
-
2527
-
2528
-
2529
Data Sheet 1_Trends in lower extremity peripheral arterial disease incidence since 1990 and forecasting future statistics using Global Burden of Disease 2021: a time-series analysi...
Published 2025“…Background<p>Lower extremity peripheral arterial disease (LEPAD) significantly affects quality of life and is associated with severe cardiovascular risks. …”
-
2530
Baseline characteristics of the study sample<sup>β</sup>μ.
Published 2024“…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”
-
2531
The flow diagram of the study (CONSORT, 2010).
Published 2024“…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”
-
2532
-
2533
-
2534
-
2535
-
2536
Sensitivity analysis.
Published 2025“…According to the follow-up, 271 (56.7%) were in the exclusive breastfeeding group and the rest in the non-exclusive breastfeeding group (n = 207, 43.3%). A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”
-
2537
Characteristics of participants.
Published 2025“…According to the follow-up, 271 (56.7%) were in the exclusive breastfeeding group and the rest in the non-exclusive breastfeeding group (n = 207, 43.3%). A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”
-
2538
Participant Flowchart.
Published 2025“…According to the follow-up, 271 (56.7%) were in the exclusive breastfeeding group and the rest in the non-exclusive breastfeeding group (n = 207, 43.3%). A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”
-
2539
Stratified analyses.
Published 2025“…According to the follow-up, 271 (56.7%) were in the exclusive breastfeeding group and the rest in the non-exclusive breastfeeding group (n = 207, 43.3%). A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”
-
2540